Hsbc Holdings PLC Sells 9,406 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Hsbc Holdings PLC reduced its stake in Prestige Consumer Healthcare Inc. by 22.0%, selling 9,406 shares to hold a total of 33,276 shares valued at approximately $2.86 million.
• Prestige Consumer Healthcare reported earnings of $0.95 per share, missing analyst estimates, and its revenue decreased by 6.6% year-over-year, totaling $249.53 million.
• Analysts currently maintain a consensus rating of "Moderate Buy" for Prestige Consumer Healthcare with an average target price of $93.33, despite recent downgrades from some research firms.

Hsbc Holdings PLC cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 22.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,276 shares of the company's stock after selling 9,406 shares during the period. Hsbc Holdings PLC owned approximately 0.07% of Prestige Consumer Healthcare worth $2,860,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Cerity Partners LLC boosted its stake in Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock valued at $315,000 after buying an additional 132 shares during the last quarter. KBC Group NV boosted its stake in Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock valued at $189,000 after buying an additional 151 shares during the last quarter. McIlrath & Eck LLC boosted its stake in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock valued at $75,000 after buying an additional 154 shares during the last quarter. Xponance Inc. boosted its stake in Prestige Consumer Healthcare by 5.5% during the first quarter. Xponance Inc. now owns 3,766 shares of the company's stock valued at $324,000 after buying an additional 196 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. boosted its stake in Prestige Consumer Healthcare by 2.3% during the first quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company's stock valued at $783,000 after buying an additional 203 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Price Performance

NYSE:PBH opened at $66.52 on Wednesday. The firm has a market capitalization of $3.27 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.07 and a beta of 0.43. Prestige Consumer Healthcare Inc. has a 1 year low of $62.95 and a 1 year high of $90.04. The business has a 50 day simple moving average of $74.59 and a 200-day simple moving average of $80.93. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.01 by ($0.06). The company had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. Prestige Consumer Healthcare's revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Analyst Upgrades and Downgrades

PBH has been the subject of a number of research reports. Canaccord Genuity Group dropped their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Royal Bank Of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.